Health and Healthcare

Gilead Sciences : GILD

All Gilead Sciences Articles

730 Articles

Chris Lange | Nov 12, 2014 at 8:40 AM EST

Biotech Short Interest Becomes Stock Specific (Updated)

24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies, such as Ebola-vaccine companies.

Lee Jackson | Oct 30, 2014 at 8:55 AM EDT

Top Health Care and Biotech Stocks to Buy That Have Already Posted Earnings

A new research note from Cowen focuses on health care companies that have released earnings and offer investors reasons to…

Chris Lange | Oct 29, 2014 at 7:55 AM EDT

Gilead Sciences Earnings Miss on Dwindling Sovaldi Sales

Gilead Sciences reported disappointing third-quarter results after the market close on Monday.

Chris Lange | Oct 28, 2014 at 11:55 AM EDT

What to Look For in Gilead Sciences Earnings Report

Gilead Sciences is set to report its third-quarter earnings after the U.S. markets close on Tuesday.

Chris Lange | Oct 27, 2014 at 10:30 AM EDT

Biotech Short Interest Becomes Stock Specific

Short interest in biotech leaders changed from directional to stock specific in the first two weeks of October.

Lee Jackson | Oct 13, 2014 at 8:40 AM EDT

UBS Very Positive on Top Biotech Stocks Ahead of Earnings

Rising trends in prescriptions and higher, yet beatable increases in earnings have set the table for what the UBS biotech…

Lee Jackson | Oct 8, 2014 at 9:00 AM EDT

Deutsche Bank’s Top Stocks to Buy Now for This Quarter and 2015

In a new research report, Deutsche Bank analysts suggest investors focus on sectors like technology, health care, financials and selected…

Lee Jackson | Oct 2, 2014 at 9:50 AM EDT

Merrill Lynch’s Top Catalyst Ideas for the Fourth Quarter

A new research report from Merrill Lynch highlights 10 top catalyst-driven ideas for the fourth quarter.

Jon C. Ogg | Sep 25, 2014 at 10:50 AM EDT

Short Sellers Make Moves in Key Biotech Stocks

Short sellers are often active in biotech stocks, and we have seen some excessive short interest activity in the most…

Lee Jackson | Sep 15, 2014 at 10:55 AM EDT

U.S. Hepatitis Problem to Continue Driving These 4 Top Stocks

A new research report from UBS focuses on four top companies that are making great strides in treatments for patients…

Chris Lange | Sep 11, 2014 at 9:20 AM EDT

Short Sellers Remain Vigilant Against Biotechs

Short sellers are often active in biotech stocks, and we have seen some excessive short interest activity in the latest…

Lee Jackson | Sep 9, 2014 at 8:30 AM EDT

Deutsche Bank’s 4 Top Biotech Stocks to Buy for This Year and 2015

A new report from the biotech team at Deutsche Bank fields questions from clients asking for specific stocks to buy…

Jon C. Ogg | Aug 15, 2014 at 8:18 AM EDT

Top Analyst Upgrades and Downgrades: Achillion, Monster, Gilead, JCPenney, JDSU, Green Mountain and More

Jon OggStocks were firm yet again on Friday morning ahead of the PPI wholesale inflation report. Investors have been trying…

Jon C. Ogg | Aug 11, 2014 at 7:51 AM EDT

Top Analyst Upgrades and Downgrades: Achillion, Gap, GNC, King Digital, Pepsi, Tesla and More

Jon OggStocks were firm on Monday morning, looking to add to the recovery bounce from Friday. Investors have now been…

Lee Jackson | Aug 6, 2014 at 9:45 AM EDT

Oppenheimer Adds 5 Triple-Play Rated Stocks to Buy

In a new report from Oppenheimer, analysts combine their fundamental rating on a company of Outperform with positive earnings revisions,…

1 … 34 35 36 37 38 … 49

Gilead Sciences : GILD

All Gilead Sciences Articles

Biotech Short Interest Becomes Stock Specific (Updated)

Top Health Care and Biotech Stocks to Buy That Have Already Posted Earnings

Gilead Sciences Earnings Miss on Dwindling Sovaldi Sales

What to Look For in Gilead Sciences Earnings Report

Biotech Short Interest Becomes Stock Specific

UBS Very Positive on Top Biotech Stocks Ahead of Earnings

Deutsche Bank’s Top Stocks to Buy Now for This Quarter and 2015

Merrill Lynch’s Top Catalyst Ideas for the Fourth Quarter

Short Sellers Make Moves in Key Biotech Stocks

U.S. Hepatitis Problem to Continue Driving These 4 Top Stocks

Short Sellers Remain Vigilant Against Biotechs

Deutsche Bank’s 4 Top Biotech Stocks to Buy for This Year and 2015

Top Analyst Upgrades and Downgrades: Achillion, Monster, Gilead, JCPenney, JDSU, Green Mountain and More

Top Analyst Upgrades and Downgrades: Achillion, Gap, GNC, King Digital, Pepsi, Tesla and More

Oppenheimer Adds 5 Triple-Play Rated Stocks to Buy

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy’s 25% Savings Rule Actually Starts at 15%

A 71-Year-Old's $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy's 25% Savings Rule Actually Starts at 15%

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Gilead Sciences : GILD

All Gilead Sciences Articles

Biotech Short Interest Becomes Stock Specific (Updated)

Top Health Care and Biotech Stocks to Buy That Have Already Posted Earnings

Gilead Sciences Earnings Miss on Dwindling Sovaldi Sales

What to Look For in Gilead Sciences Earnings Report

Biotech Short Interest Becomes Stock Specific

UBS Very Positive on Top Biotech Stocks Ahead of Earnings

Deutsche Bank’s Top Stocks to Buy Now for This Quarter and 2015

Merrill Lynch’s Top Catalyst Ideas for the Fourth Quarter

Short Sellers Make Moves in Key Biotech Stocks

U.S. Hepatitis Problem to Continue Driving These 4 Top Stocks

Short Sellers Remain Vigilant Against Biotechs

Deutsche Bank’s 4 Top Biotech Stocks to Buy for This Year and 2015

Top Analyst Upgrades and Downgrades: Achillion, Monster, Gilead, JCPenney, JDSU, Green Mountain and More

Top Analyst Upgrades and Downgrades: Achillion, Gap, GNC, King Digital, Pepsi, Tesla and More

Oppenheimer Adds 5 Triple-Play Rated Stocks to Buy

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy’s 25% Savings Rule Actually Starts at 15%

Featured Reads

A 71-Year-Old's $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy's 25% Savings Rule Actually Starts at 15%